Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults, With Optional Open-Label Extension

NCT05219617 is registered in ClinicalTrials.gov with SK Life Science, Inc. as lead sponsor.

NCT NCT05219617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05219617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults, With Optional Open-Label Extension
Lead sponsor
SK Life Science, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
April 28, 2022
Completion date
December 31, 2028
Enrollment
252 (estimated)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

lennox gastaut syndrome, seizures